ADC Therapeutics (ADCT) Current Assets (2019 - 2026)

ADC Therapeutics has disclosed Current Assets across 8 years of filings, most recently posting $276.8 million for Q1 2026.

• Current Assets for Q1 2026 came in at $276.8 million, up 7.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $276.8 million (up 7.28% YoY), and the FY2025 annual result was $306.3 million, up 5.18% from the prior year.
• Current Assets came in at $276.8 million for Q1 2026 at ADC Therapeutics, down from $306.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $435.0 million in Q4 2022 to a low of $258.0 million in Q1 2025.
• The 5-year median for Current Assets is $306.3 million (2025), against an average of $317.1 million.
• Across the five-year window, Current Assets decreased 22.69% in 2023 and gained 7.28% in 2026, its largest moves.
• ADC Therapeutics' Current Assets stood at $435.0 million in 2022, then fell by 22.69% to $336.3 million in 2023, then fell by 13.39% to $291.3 million in 2024, then gained by 5.18% to $306.3 million in 2025, then fell by 9.65% to $276.8 million in 2026.
• The last three Current Assets figures came in at $276.8 million (Q1 2026), $306.3 million (Q4 2025), and $287.1 million (Q3 2025), per Business Quant data.